



General Assembly

February Session, 2006

Substitute Bill No. 5637

* _____ HB05637HS_APP032106 _____ *

**AN ACT CONCERNING THE AVAILABILITY OF TEMPORARY
SUPPLIES OF BRAND NAME DRUGS.**

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective July 1, 2006*) (a) In all cases where a
2 Medicaid or state-administered general assistance recipient presents to
3 a pharmacist a prescription for a drug that is subject to the prior
4 approval requirements, but for which prior approval has not been
5 obtained, the Department of Social Services, an independent pharmacy
6 consultant acting on behalf of the department or any entity that
7 administers a Medicaid or state-administered general assistance
8 managed care health plan shall, upon receiving an electronic request
9 for payment of such drug:

10 (1) Ensure the immediate electronic authorization of up to a
11 thirty-day temporary supply of the originally prescribed drug;

12 (2) Provide notification to the practitioner, not later than twenty-
13 four hours after presentation of the prescription at the pharmacy, by
14 facsimile transmission or electronic mail, that (A) prior approval is
15 required for the prescribed drug, (B) there is a specified process for
16 obtaining prior approval, together with forms that may be transmitted
17 electronically to obtain such approval, (C) a temporary supply of the
18 prescribed drug, not to exceed thirty days, was issued in the absence of
19 prior approval, and (D) identifies any alternative drugs contained on

20 the applicable preferred drug lists that may be equally effective; and

21 (3) Mail written notification to the Medicaid or state-administered
22 general assistance recipient, not later than twenty-four hours after
23 presentation of the prescription at the pharmacy, that (A) prior
24 approval is required for the prescribed drug, (B) a temporary supply of
25 the prescribed drug was issued in the absence of prior approval, and
26 (C) the practitioner has been advised of the option of requesting prior
27 authorization for the originally prescribed drug or prescribing
28 alternative drugs contained on the preferred drug lists, that may be
29 equally effective.

30 (b) The Department of Social Services, an independent pharmacy
31 consultant acting on behalf of the department, or any entity that
32 administers a Medicaid or state-administered general assistance
33 managed care health plan shall provide written notice of the right to a
34 hearing to a Medicaid or state-administered general assistance
35 recipient whenever the department, such consultant or entity: (1)
36 Authorizes less than the full amount or duration of the drug originally
37 prescribed, (2) denies or terminates payment for a prescribed drug,
38 including termination of payment after providing a temporary supply
39 of the prescribed drug, or (3) denies a request for prior approval of a
40 prescribed drug. The hearing shall be administered by the department
41 pursuant to chapter 54 of the general statutes.

42 Sec. 2. Subsection (b) of section 17b-274 of the 2006 supplement to
43 the general statutes is repealed and the following is substituted in lieu
44 thereof (*Effective July 1, 2006*):

45 (b) A licensed medical practitioner may specify in writing or by a
46 telephonic or electronic communication that there shall be no
47 substitution for the specified brand name drug product in any
48 prescription for a Medicaid, state-administered general assistance, or
49 ConnPACE recipient, provided (1) the practitioner specifies the basis
50 on which the brand name drug product and dosage form is medically
51 necessary in comparison to a chemically equivalent generic drug

52 product substitution, and (2) the phrase "brand medically necessary"
 53 shall be in the practitioner's handwriting on the prescription form or, if
 54 the prohibition was communicated by telephonic communication, in
 55 the pharmacist's handwriting on such form, and shall not be
 56 preprinted or stamped or initialed on such form. If the practitioner
 57 specifies by telephonic communication that there shall be no
 58 substitution for the specified brand name drug product in any
 59 prescription for a Medicaid, state-administered general assistance, or
 60 ConnPACE recipient, written certification in the practitioner's
 61 handwriting bearing the phrase "brand medically necessary" shall be
 62 sent to the dispensing pharmacy within ten days. [A] Except as
 63 provided in section 1 of this act, a pharmacist shall dispense a
 64 generically equivalent drug product for any drug listed in accordance
 65 with the Code of Federal Regulations Title 42 Part 447.332 for a drug
 66 prescribed for a Medicaid, state-administered general assistance, or
 67 ConnPACE recipient unless the phrase "brand medically necessary" is
 68 ordered in accordance with this subsection and such pharmacist has
 69 received approval to dispense the brand name drug product in
 70 accordance with subsection (c) of this section.

71 Sec. 3. Subsection (f) of section 17b-274d of the 2006 supplement to
 72 the general statutes is repealed and the following is substituted in lieu
 73 thereof (*Effective July 1, 2006*):

74 (f) [Nonpreferred] Except as provided in section 1 of this act,
 75 nonpreferred drugs in the classes of drugs included on the preferred
 76 drug lists shall be subject to prior authorization. If prior authorization
 77 is granted for a drug not included on a preferred drug list, the
 78 authorization shall be valid for one year from the date the prescription
 79 is first filled. Mental-health-related and antiretroviral classes of drugs
 80 shall not be included on the preferred drug lists.

This act shall take effect as follows and shall amend the following sections:

Section 1	July 1, 2006	New section
-----------	--------------	-------------

Sec. 2	<i>July 1, 2006</i>	17b-274(b)
Sec. 3	<i>July 1, 2006</i>	17b-274d(f)

HS*Joint Favorable Subst. C/R*

APP